Skip to content

Trial Objectives

Mycobacterium avium complex (MAC) is the most common cause of nontuberculous mycobacteria (NTM)-associated lung disease in the U.S. It can result in a serious infection and damage to the lungs, especially affecting people with conditions such as lung diseases, autoimmune disorders or medical treatments that compromise the immune system.

In the ENCORE study, researchers are evaluating the effectiveness and safety profile of a study medication on people who have been diagnosed with Nontuberculous Mycobacterial (NTM) lung infection caused by Mycobacterium avium complex (MAC).

By participating in this study, you contribute to the understanding of MAC lung infection, and the information gathered (including information obtained from the sputum, blood sampling and the other tests you complete) may help other patients with MAC lung infections in the future.

Who Can Participate

Adults ages 18 and older with a diagnosis of lung infection caused by Mycobacterium avium complex within the last six months.

Age: 18+ Gender: Any

Estimated Time Commitment

16 study visits over approximately 70 weeks. Five of the visits can be done over the phone instead of in person.

Payment & Reimbursement

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Cynthia Wainscoat

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors


Principal Investigators

Charles L. Daley

Charles L. Daley, MD


David E. Griffith

David E. Griffith, MD

Request more Information

By completing this form, you agree to learn more about this study and see if you qualify.

I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health required